Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Is dabigatran considered a cost-effective alternative to warfarin treatment: a review of current economic evaluations worldwide.

Hesselbjerg LJ, Pedersen HS, Asmussen MB, Petersen KD.

J Med Econ. 2013 Jul;16(7):845-58. doi: 10.3111/13696998.2013.800523. Epub 2013 May 15. Review.

2.

Dabigatran for the prevention of stroke and systemic embolism in atrial fibrillation: A NICE single technology appraisal.

Faria R, Spackman E, Burch J, Corbacho B, Todd D, Pepper C, Woolacott N, Palmer S.

Pharmacoeconomics. 2013 Jul;31(7):551-62. doi: 10.1007/s40273-013-0051-8. Review.

PMID:
23620211
3.

Dabigatran etexilate: a pharmacoeconomic review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.

McKeage K.

Pharmacoeconomics. 2012 Sep 1;30(9):841-55. doi: 10.2165/11209130-000000000-00000. Review.

PMID:
22734683
4.

Is dabigatran cost effective compared with warfarin for stroke prevention in atrial fibrillation? A critically appraised topic.

Adcock AK, Lee-Iannotti JK, Aguilar MI, Hoffman-Snyder CR, Wingerchuk DM, Wellik KE, Demaerschalk BM.

Neurologist. 2012 Mar;18(2):102-7. doi: 10.1097/NRL.0b013e318247bcb6. Review.

PMID:
22367842
5.

Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients.

[No authors listed]

Prescrire Int. 2012 Feb;21(124):33-6. Review.

PMID:
22413715
6.

An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.

Mantha S, Ansell J.

Thromb Haemost. 2012 Sep;108(3):476-84. doi: 10.1160/TH12-02-0093. Epub 2012 Jun 28. Review.

PMID:
22740145
7.

Potential impact of new oral anticoagulants on the management of atrial fibrillation-related stroke in primary care.

Harris K, Mant J.

Int J Clin Pract. 2013 Jul;67(7):647-55. doi: 10.1111/ijcp.12177. Epub 2013 Apr 28. Review.

8.

Use of novel oral anticoagulants for patients with atrial fibrillation: systematic review and clinical implications.

Albert NM.

Heart Lung. 2014 Jan-Feb;43(1):48-59. doi: 10.1016/j.hrtlng.2013.10.014. Epub 2013 Nov 11. Review.

PMID:
24373340
9.

New evidences for old concerns with oral anticoagulation in atrial fibrillation: focus on dabigatran.

Barrios V, Escobar C.

Expert Opin Pharmacother. 2012 Dec;13(18):2649-61. doi: 10.1517/14656566.2012.749860. Epub 2012 Nov 20. Review.

PMID:
23167273
10.

Dabigatran and factor Xa inhibitors for stroke prevention in patients with nonvalvular atrial fibrillation.

Uchiyama S, Ibayashi S, Matsumoto M, Nagao T, Nagata K, Nakagawara J, Tanahashi N, Tanaka K, Toyoda K, Yasaka M.

J Stroke Cerebrovasc Dis. 2012 Apr;21(3):165-73. doi: 10.1016/j.jstrokecerebrovasdis.2012.01.011. Review.

PMID:
22440950
11.

Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.

Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ.

Am J Cardiol. 2012 Aug 1;110(3):453-60. doi: 10.1016/j.amjcard.2012.03.049. Epub 2012 Apr 24. Review.

PMID:
22537354
12.

Home-monitoring of oral anticoagulation vs. dabigatran. An indirect comparison.

Alonso-Coello P, Zhou Q, Guyatt G.

Thromb Haemost. 2012 Oct;108(4):647-53. Epub 2012 Aug 23. Review.

PMID:
22918481
13.

Benefit-risk assessment of dabigatran in the treatment of stroke prevention in non-valvular atrial fibrillation.

Meyer Dos Santos S, Harder S.

Drug Saf. 2014 May;37(5):295-307. doi: 10.1007/s40264-014-0151-1. Review.

PMID:
24683059
14.

Dabigatran for stroke prevention in nonvalvular atrial fibrillation: focus in the geriatric population.

Brunetti L, Chen C, White J.

Consult Pharm. 2014 Mar;29(3):169-78. doi: 10.4140/TCP.n.2014.169. Review.

PMID:
24589766
15.

Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation.

Salazar CA, del Aguila D, Cordova EG.

Cochrane Database Syst Rev. 2014 Mar 27;(3):CD009893. doi: 10.1002/14651858.CD009893.pub2. Review.

PMID:
24677203
16.

Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.

Harenberg J, Marx S, Diener HC, Lip GY, Marder VJ, Wehling M, Weiss C.

Int Angiol. 2012 Aug;31(4):330-9. Review.

PMID:
22801398
17.

Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results.

Pengo V, Crippa L, Falanga A, Finazzi G, Marongiu F, Moia M, Palareti G, Poli D, Testa S, Tiraferri E, Tosetto A, Tripodi A, Siragusa S, Manotti C.

J Thromb Haemost. 2012 Oct;10(10):1979-87. doi: 10.1111/j.1538-7836.2012.04866.x. Review.

18.

Atrial fibrillation and dabigatran: has the time come to use new anticoagulants?

Escobar C, Barrios V, Jimenez D.

Cardiovasc Ther. 2010 Oct;28(5):295-301. doi: 10.1111/j.1755-5922.2010.00216.x. Epub 2010 Aug 16. Review.

PMID:
20718760
19.

[Dabigatran eteksilat new anticoagulant for the prevention of stroke in patients with atrial fibrillation without valvular lesions].

Panchenko EP.

Kardiologiia. 2011;51(11):83-90. Review. Russian. No abstract available.

PMID:
22117775
20.

Stop the clots, but at what cost? Pharmacoeconomics of dabigatran etexilate for the prevention of stroke in subjects with atrial fibrillation: a systematic literature review.

Marshall S, Fearon P, Dawson J, Quinn TJ.

Expert Rev Pharmacoecon Outcomes Res. 2013 Feb;13(1):29-42. doi: 10.1586/erp.12.79. Review.

PMID:
23402443

Supplemental Content

Support Center